We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byTatum Eagleton
Modified about 1 year ago
A single dose of erythropoietin in ST-elevation myocardial infarction by Adriaan A. Voors, Anne M.S. Belonje, Felix Zijlstra, Hans L. Hillege, Stefan D. Anker, Riemer H.J.A. Slart, René A. Tio, Arnoud van ‘t Hof, J. Wouter Jukema, Hans Otto J. Peels, José P.S. Henriques, Jurriën M. ten Berg, Jeroen Vos, Wiek H. van Gilst, Dirk J. van Veldhuisen, and EHJ Volume 31(21): November 1, 2010 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please
Flowchart representing number of patients randomized to erythropoietin or control, and patients who dropped out for provided reasons. Adriaan A. Voors et al. Eur Heart J 2010;31: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please
Primary endpoint; mean left ventricular ejection fraction (± standard deviation) of patients treated with erythropoietin and of patients in the control group, 6 weeks after a successful primary coronary intervention. Adriaan A. Voors et al. Eur Heart J 2010;31: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please
Secondary outcome: Kaplan–Meier curves indicating pre-defined cardiovascular events within 6 weeks after a successful primary coronary intervention for a first ST-elevation myocardial infarction in patients treated with a single high dose of erythropoietin or control patients. Adriaan A. Voors et al. Eur Heart J 2010;31: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
Inequalities across Europe in access to primary angioplasty to treat acute heart attack patients -the cross-border dimension- John Martin, MD, FRCP, FESC,
The prevalence of use of beta- blockers in secondary prevention of myocardial infarctions in patients hospitalized 1 Institute of Epidemiology and biostatistics,
Eur Heart J 2013; 34: Heterozygous familial hypercholesterolaemia (FH) Nordestgaard et al. Eur Heart J 2013; 34:
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
1 Outcomes for Patients with ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York.
Electrophysiology 2011 Taresh Taneja, MD, FACC Assistant Professor of Medicine Texas A & M HSC COM Scott & White Hospital.
AF and the New Oral Anti-Coagulants Evidenced based approach. Adapted from ESC guidelines. Dr Raj Chahal, Cardiology Trainee November 2013.
Patient Oriented Therapy for STE-MI Seçkin Pehlivanoğlu, MD Başkent University, İstanbul Hospital.
RACE II RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity.
NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction.
An audit of the antithrombotic therapy for the management of valve repair or replacement Gellatly RM 1,2, Maydelmin D 1, Connell C 1, Marasco S 3, Zimmet.
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
Chronic heart failure Implementing NICE guidance 2 nd. Edition – June 2011 NICE clinical guideline 108.
Five year clinical follow-up of the PASSION-trial Five year clinical follow-up of the PASSION-trial Five Year Follow-up after Primary PCI with a Paclitaxel-Eluting.
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial CIBIS III Trial Presented at The European Society of Cardiology Hot Line Session 2005 Presented.
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.
Presenter Disclosure Information Robert E. Michler, M.D. Influence of Left Ventricular Volume Reduction on Outcome After Coronary Artery Bypass Grafting.
Patient Oriented Therapy Non STE ACS Prof dr Midhat nurkić FESC Director clinic for cardiovascular disease UKC Tuzla.
Title Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Clinical Trial Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with.
SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt.
AHA/ASA Guideline Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals.
Cardiopatia ischemica: nuovi orizzonti nella terapia con antiaggreganti orali Giancarlo Casolo Genova, Hotel NH Marina 21/22 Ottobre 2011 HEARTLINE HSM.
Diagnostic Accuracy of Fractional Flow Reserve from Anatomic Computed TOmographic Angiography: The DeFACTO Study James K. Min 1 ; Jonathon Leipsic 2 ;
Atrial Fibrillation: Clinical Significance, Mechanisms, and Treatments Alexander Burashnikov PhD, FHRS Cardiac Research Institute Masonic Medical Research.
© 2010, American Heart Association. All rights Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality.
Bias in Clinical Trials. Bias Having a preference to one particular person / group / point of view - “one-sided inclination” Prejudice – negative.
© 2016 SlidePlayer.com Inc. All rights reserved.